The literal store is configured by default. Systematic reviews combine the results of many studies. Please help us protect Glassdoor by verifying that you're a Become a data scientist to help businesses leverage data, analyze data, and provide data-driven insights so businesses can make informed decisions. This cookie is set by GDPR Cookie Consent plugin. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie If youre feeling stumped, take a guess and move on. Can early US adoption of cancer drugs inform HTA decision making? When you choose to start a program at Flatiron School, we know that you are investing both financially and an investment of your time. The test is a good indicator of strategic thinking, how quickly you pick up new concepts and how well you cope under pressure. Estep internalizes the impact of saying no for the physician and patient on the other end of that decision but has learned to leverage the power of compassion. Take a look at some of the features that set Medical Record Abstraction apart: Scalable staff. There is a time clock on the page so you will know how many questions you have completed and how much time remains. We don't expect you to complete all the questions. After you finish and submit the admissions test, your score is recorded in our system and you will receive a link to schedule your interview at the end of the assessment. Tedious work for very poor pay. Experience from Electronic Health Records (EHR), Olaratumab for the Treatment of Patients (pts) with Advanced/Metastatic Soft Tissue Sarcoma (STS): Treatment Patterns in the United States (US) During the First Year Post-Approval, Emergent Renal and Hepatic Dysfunction (dys) in a Real-World Cohort of Advanced Melanoma (aMel) Patients (pts) Receiving First Line (1L) Immune Checkpoint Inhibitors (ICIs), Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US, Impact of Flexible Assessment Schedules on Treatment Effect Bias in Pragmatic Clinical Trials, Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC), Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB), Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database, Ramucirumab (ram), Immune Checkpoint Inhibitors (ICIs), and Single-Agent Chemotherapy (chemo) Usage in Real-World Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (pts) after Rapid Disease Progression (RDP) on Platinum (Pt), ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive, Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network, Oncology Data Abstraction: Leveraging the Clinical Expertise of Oncology Nurses to Unlock Clinical Insights from Data in Electronic Health Records, Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database, Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden, An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States, Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032, Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database, Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database, Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT), Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States, Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States, Multiple Myeloma Patients and Risk of Skeletal Related Events Real-World Evidence in US Oncology Clinics, Population Characteristics and Utilization Patterns of Patients Treated with Palbociclib Over 2 Years of Post-Approval, Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors, Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer using Electronic Health Record with Proper Quality Control Versus Conventional PFS from a Phase 3 Trial, Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC), Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC, ALK Testing Trends and Patterns Among Community Practices in the United States, Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US, Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States, Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC), Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database, Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database, Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States, Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database, Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States, Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors, Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors, Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer, Development and Validation of a Real-World Clinico-Genomic Database, The Application of Electronic Medical Records (Emrs) As a Virtual Comparator Arm in a Lung Cancer Clinical Trial: a Case Study, Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation, Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice, Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database, Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma, Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Implementation of the IOM 13 Point Care Plan by OCM Practices, Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience, Rates of PD-L1 Expression Testing in US Community-Based Oncology Practices for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab or Pembrolizumab, Retrospective Indirect Comparison of Alectinib Phase II Data vs Ceritinib Real-World Data in ALK+ NSCLC After Progression on Crizotinib, The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology, Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks, Real-World Concordance of Clinical Practice with ASCO and NCCN Guidelines for EGFR/ALK Testing in aNSCLC, Treatment Sequences in Non-Small Cell Lung Cancer in the United States From 2014-2016, Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry, The Treatment Continuum of Panitumumab, Cetuximab, and Bevacizumab in 1st Through 3rd Line by KRAS, NRAS, and BRAF Mutation Status Among mCRC Patients Treated at Community Cancer Centers in the United States, Real-World Treatment Patterns for Advanced EGFR Wild-type NSCLC in Second Or Third Line in a Large US Database, Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data, Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-line Setting as Assessed Using a Novel Electronic Health Record Database, Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-inhibitor Treated Patients, Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data, Treatment Patterns for Metastatic Melanoma in US Community Oncology Clinical Practice: A Retrospective Observational Study, Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer, Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort, Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States, Characterization of KRAS, BRAS, and BRAF Testing and Timing Among mCRC Patients Treated At Community Cancer Centers in the United States, Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma, BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma, Improving misclassification of ICD-9 coding for bone metastases in electronic medical records (EMR) using technology-enabled abstraction.